Graft Polymer (UK) PLC (GB:GPL) has released an update.
Graft Polymer (UK) PLC has successfully raised £1.8 million through a share placement to fund administrative expenses, working capital, research and development, and marketing. The company, specializing in biopolymer drug delivery systems, recently filed patents for their self-nanoemulsifying drug delivery system (SNEDDS) aimed at substance use disorders and mental health treatments, and is exploring commercial partnerships in the healthcare sector. Amidst challenging trading conditions, Graft Polymer has also strategically refocused on its Graft Bio division and disposed of its Slovenian polymer division.
For further insights into GB:GPL stock, check out TipRanks’ Stock Analysis page.
